In a release, the Company noted that the LifeVest is worn by patients at risk of sudden cardiac arrest (SCA), allowing their physicians time to assess their long-term arrhythmic risk and make appropriate plans. The LifeVest is lightweight, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCA. The LifeVest does not require bystander intervention and has a 98 percent first treatment shock success rate for resuscitating patients with SCA.
"The LifeVest offers patients the potential for protection from SCA in the highest risk period immediately following a myocardial infarction when other therapies are not indicated due to a patient's temporary or changing condition," said Dr. Ranjit Suri, Director of Electrophysiology Service and Cardiac Arrhythmia Center at Lenox Hill Heart and Vascular Institute of New York, which was named to the 50 Best Heart and Heart Surgery hospital list. "The LifeVest is an important part of the continuum of care to protect our patients at risk of SCA."
"We believe the continued prescription of the LifeVest in each of the nation's premier hospitals demonstrates that the LifeVest is developing as a standard of care for patients with a temporary risk of sudden cardiac death," said Richard A. Packer, Chairman and Chief Executive Officer of Zoll.
The Company noted that the LifeVest may be prescribed for patients following a heart attack, before or after bypass surgery or stent placement, as well as for those with cardiomyopathy or congestive heart failure that places them at particular risk. It may also be prescribed for patients whose comorbidities, including infections caused by placement of ICDs, prevent them undergoing immediate implant surgery for an ICD. To date, the LifeVest has been prescribed to more than 18,000 patients.
((Comments on this story may be sent to health@closeupmedia.com))

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index